Please ensure Javascript is enabled for purposes of website accessibility

Clover Health Stock Sinks After Short-Seller Allegations: 3 Key Things to Know

By Keith Speights - Updated Feb 5, 2021 at 9:27AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Most important: Don't jump the gun on any conclusions.

Billionaire investor Chamath Palihapitiya recently took Clover Health Investments (CLOV -0.49%) public through one of his special purpose acquisition companies (SPACs). He has pointed to the Medicare Advantage plan provider as "the greatest growth opportunity" that he's seen

But Clover Health stock isn't going in the right direction. Shares plunged more than 10% on Thursday after short-seller Hindenburg Research posted a scathing report online that referred to Clover Health as "a broken company." Here are three key things you need to know.

Man wearing a coat and tie holding a red line trending downward

Image source: Getty Images.

1. The allegations

Hindenburg Research's allegations can be summed up as follows:

  1. The company hasn't disclosed that it's under investigation by the U.S. Department of Justice (DOJ).
  2. The company's sales are driven by misleading marketing practices.
  3. The company's Clover Assistant software "deceives the healthcare system" and "poses a significant regulatory risk."

The short-seller pointed to a Civil Investigative Demand (CID) related to an investigation by the DOJ into whether or not Clover Health "improperly induced patient referrals for services paid for by Federal agencies." The online report stated that Clover Health has failed to disclose this investigation.

Hindenburg's second allegation is based on the belief that the issues that the DOJ is investigating have merit. In particular, the online report maintained that Seek Insurance Services, a subsidiary of Clover Health, "misleadingly markets itself as providing 'independent' and 'unbiased' advice to seniors looking for Medicare."

The short-seller alleged that much of Clover Health's sales stem from a brokerage controlled by the company's head of sales. It also cited former employees of Clover who reportedly said that the company has paid physicians' office staff to refer seniors to Clover's Medicare Advantage plans.

In addition, Hindenburg claimed that the Clover Assistant software is designed to enable healthcare professionals to game the Medicare system by not removing old diagnoses that are no longer applicable. If this happened, it would make patients appear to be sicker than they really were and increase Medicare reimbursement payments.

2. Potential implications for Clover Health

Probably the most serious allegation made by Hindenburg research is that the company has compensated physicians' staff to refer patients to its Medicare plans. Paying for referrals to federal healthcare programs is illegal.

The potential penalties for anyone found guilty of this include fines of up to $250,000. Individuals convicted of Medicare fraud can be sentenced to jail for up to 10 years in some cases. 

The immediate implication for Clover Health, though, is the toll the allegations have taken on the healthcare stock itself. It's likely that the stock could remain highly volatile until the company can move past the cloud hanging over it related to Hindenburg's report and the DOJ investigation. 

3. Too soon to draw conclusions

For investors, the most important thing to know is that drawing any conclusions is premature at this point. Clover Health hasn't publicly responded to Hindenburg Research's allegations. It's always good to hear both sides of a story before deciding what you think.

As for the Civil Investigative Demand issued by the DOJ, it's basically like a subpoena. Just because one is issued doesn't necessarily mean that actual problems exist. These investigations often fizzle out.

It's worth noting, though, that while Hindenburg Research is a short-seller, the company stated that it doesn't have any position in Clover Health stock. Usually, when short-sellers post allegations about a company, they have a financial interest in driving the share price lower.

The bottom line is that more facts are needed. Clover Health could be damaged, at least to some extent, if Hindenburg's allegations are borne out. The company could also emerge from the controversy clean as a whistle and become the tremendous growth story that Chamath Palihapitiya thinks it is. The best thing to do is wait for the dust to settle. 

This article represents the opinion of the writer, who may disagree with the "official" recommendation position of a Motley Fool premium advisory service. We're motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become Smarter, Happier, and Richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clover Health Investments, Corp. Stock Quote
Clover Health Investments, Corp.
CLOV
$2.56 (-0.49%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.